---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-24-000043"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2024-04-26T23:59:59+00:00"
generated_at: "2026-06-03T06:31:27.413290+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BeiGene provides additional 2023 financial data including regional gross margins and product R&D

## Summary
- Total revenue $2.46B; China gross margin 68.0% (2022: 67.1%), ex-China 98.0% (98.3%).
- R&D expense by product: zanubrutinib $158M, tislelizumab $84M, pamiparib $9M, ociperlimab $78M.
- Total R&D expenses $1.78B in 2023 vs $1.64B in 2022; internal R&D $1.13B.
- Key products produced 5.0M vials, sold 3.88M vials; inventory 2.67M vials as of Dec 31, 2023.

## SEC filing metadata
- accession: 0001651308-24-000043
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2024-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000043/0001651308-24-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000043/bgne-20240426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-24-000043
- JSON: https://secwatch.observer/filing/0001651308-24-000043.json
- Plain text: https://secwatch.observer/filing/0001651308-24-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.